Intra-Cellular Therapies Inc. - ITCI STOCK NEWS

Intra-Cellular Therapies (Nasdaq: ITCI) announced presentations of lumateperone data at the 37th European College of Neuropsychopharmacology (ECNP) Congress in Milan, Italy. The presentations include results from Study 501, evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for Major Depressive Disorder (MDD), and post-hoc analyses from Study 403 focusing on patients with MDD or bipolar depression with mixed features and anxious distress.

In Study 501, lumateperone met the primary endpoint with a 4.9-point reduction in MADRS total score versus placebo (p<0.0001). It also met key secondary endpoints and showed a favorable safety profile. Study 502 similarly demonstrated positive results. Study 403 analyses highlighted lumateperone's efficacy in patients with anxious distress and mixed features, showing significant improvements in depression symptoms and severity.

Intra-Cellular Therapies (Nasdaq: ITCI), a biopharmaceutical company focused on CNS disorders, has announced its participation in three upcoming investor conferences. Sharon Mates, Ph.D., CEO and Chairman, will present at:

• Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, at 10:00 a.m. ET
• Baird's 2024 Global Healthcare Conference on September 11, 2024, at 11:25 a.m. ET
• 2024 Cantor Global Healthcare Conference on September 18, 2024, at 10:55 a.m. ET

All conferences will take place in New York, NY. Live and archived webcasts of the presentations will be available on the company's website under the Investors section.

Intra-Cellular Therapies (Nasdaq: ITCI), a biopharmaceutical company specializing in CNS disorder therapeutics, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. Sharon Mates, Ph.D., the company's CEO and Chairman, is scheduled to present on Tuesday, August 13, 2024, at 12:00 p.m. ET in Boston, MA.

Investors and interested parties can access the live and archived webcast of the presentation through the company's website at www.intracellulartherapies.com under the 'Events & Presentations' section in Investor Relations. Attendees are advised to log in 5-10 minutes early to register and install any necessary software for viewing the presentation.

Intra-Cellular Therapies (Nasdaq: ITCI) has announced the appointment of Sanjeev Narula as Executive Vice President and Chief Financial Officer, effective August 12, 2024. Narula, who brings extensive experience from his roles at Viatris, Pfizer, American Express, and Xerox India, will succeed Lawrence Hineline, who is retiring but will remain as a consultant to ensure a smooth transition. Dr. Sharon Mates, ITCI's Chairman and CEO, expressed excitement about Narula joining the leadership team as the company continues its rapid growth. Narula's background includes serving as CFO of Viatris and holding various financial leadership positions at Pfizer over 16 years.

Intra-Cellular Therapies (ITCI) reported strong Q2 2024 results, with CAPLYTA net product sales reaching $161.3 million, a 46% increase year-over-year. Total prescriptions for CAPLYTA grew 36% compared to Q2 2023. The company raised its 2024 CAPLYTA sales guidance to $650-$680 million.

ITCI announced positive Phase 3 results for lumateperone as an adjunctive therapy for major depressive disorder (MDD), with an sNDA submission planned for H2 2024. The company also initiated patient enrollment in Phase 2 studies for ITI-1284 in generalized anxiety disorder and Alzheimer's-related psychosis.

Despite strong sales growth, ITCI reported a net loss of $16.2 million for Q2 2024, an improvement from the $42.8 million loss in Q2 2023. The company ended the quarter with a strong cash position of $1.025 billion.

Intra-Cellular Therapies (Nasdaq: ITCI), a biopharmaceutical company specializing in central nervous system (CNS) disorder treatments, has announced a conference call and webcast for August 7, 2024, at 8:30 a.m. Eastern Time. The event will provide a corporate update and discuss financial results for the quarter ending June 30, 2024.

Participants can join the call via phone by using the provided registration link. The webcast will be accessible through the company's website under the Investor Relations section. Interested parties are advised to log in 5-10 minutes early to complete the registration process and install any necessary software.

Intra-Cellular Therapies announced positive topline results from Study 502, which evaluated lumateperone 42 mg as adjunctive therapy for Major Depressive Disorder (MDD).

The drug achieved significant and clinically meaningful results in primary and key secondary endpoints. Lumateperone 42 mg showed a 4.5-point reduction on the MADRS total score compared to placebo (p<0.0001; ES=0.56) and a significant reduction in the CGI-S score (p<0.0001; ES=0.51).

Statistically significant results were also observed on the QIDS-SR scale (p<0.0001). The safety profile was generally favorable and consistent with prior studies. An sNDA submission is anticipated in the second half of 2024.

Intra-Cellular Therapies (Nasdaq: ITCI), a biopharmaceutical company focusing on CNS disorder therapeutics, announced that its CEO, Sharon Mates, Ph.D., will present at the 45th Annual Goldman Sachs Global Healthcare Conference. The presentation is scheduled for June 11, 2024, at 10:00 a.m. ET in Miami, FL. The live and archived webcast will be available under the 'Events & Presentations' section of the company's website. Attendees are advised to log in 5-10 minutes prior to the event to register and install any necessary software.

Intra-Cellular Therapies (Nasdaq: ITCI), a biopharmaceutical company specializing in treatments for central nervous system (CNS) disorders, announced that its CEO, Sharon Mates, Ph.D., will present at the Jefferies Global Healthcare Conference. This event is scheduled for June 5, 2024, at 11:00 a.m. ET in New York, NY. A live and archived webcast will be available on the company's website under the Investor Relations section. Viewers are advised to log in 5-10 minutes early to register and install necessary software.